21 assets in Central Nervous System Leukemia

Therapeutic assets addressing Central Nervous System Leukemia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Central Nervous System Leukemia	Masonic Cancer Center, University of Minnesota	P3	BB (66)
Adriamycin Central Nervous System Leukemia	Children's Oncology Group	P3	BB (64)
Cytarabine Central Nervous System Leukemia	Children's Oncology Group	P3	BB (64)
Daunomycin Central Nervous System Leukemia	Children's Oncology Group	P3	BB (64)
Mercaptopurine Anhydrous Central Nervous System Leukemia	Children's Oncology Group	P3	BB (64)
Pegaspargase Central Nervous System Leukemia	Children's Oncology Group	P3	BB (64)
Prednisone Central Nervous System Leukemia	Children's Oncology Group	P3	BB (64)
Thioguanine Anhydrous Central Nervous System Leukemia	Children's Oncology Group	P3	BB (64)
Vincristine Sulfate Central Nervous System Leukemia	Children's Oncology Group	P3	BB (64)
Dexasone Central Nervous System Leukemia	Children's Oncology Group	P3	B (63)
Blinatumomab Central Nervous System Leukemia	Children's Oncology Group	P3	B (60)
Calaspargase Pegol Central Nervous System Leukemia	Children's Oncology Group	P3	B (60)
Inotuzumab Ozogamicin Central Nervous System Leukemia	Children's Oncology Group	P3	B (60)
Methotrexate Central Nervous System Leukemia	Children's Oncology Group	P3	B (60)
Prednisolone Central Nervous System Leukemia	Children's Oncology Group	P3	B (60)
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells Central Nervous System Leukemia	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit Central Nervous System Leukemia	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Busulfanum Central Nervous System Leukemia	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Fludarabine Central Nervous System Leukemia	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Melphalan Central Nervous System Leukemia	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Rituximab Central Nervous System Leukemia	Masonic Cancer Center, University of Minnesota	P2	CCC (53)